Evaluating an ebola vaccine regimen and booster dose among healthcare personnel of the Democratic Republic of the Congo : a step towards outbreak prevention
Source
Antwerp, University of Antwerp, Faculty of Medicine and Health Sciences, 2024,318 p.
Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo : secondary and exploratory outcomes of an open-label, randomised, phase 2 trial
Source
The lancet infectious diseases - ISSN 1473-3099- (2024) p. 1-14
Longitudinal assessment of an Ebola vaccine trial understanding among healthcare providers in the Democratic Republic of the Congo
Source
Vaccine - ISSN 0264-410X-42:3 (2024) p. 481-488
Conducting an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo : challenges, mitigations, and lessons learned
Source
Vaccine - ISSN 0264-410X-41:51 (2023) p. 7587-7597
Safety and immunogenicity of the heterologous 2-dose Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in health care providers and frontliners of the Democratic Republic of the Congo
Source
The journal of infectious diseases - ISSN 0022-1899- (2023) p. 1-9